We pursued AD-specific phosphorylations by RNAi knockdowns of upstream kinases that may target the modified GFAP sites, each of which resulted in a marked reduction in amyloid deposition by human neuroblastoma and glioma cells in vitro. This evidence concerns the gene GFAP and neuroblastoma.